Everlywell Signs Agreement to Distribute FDA-Authorized Rapid Antigen Testing for Organizations and Public Health Agencies
AUSTIN, Texas, Jan. 8, 2021 /PRNewswire/ -- Everlywell, a leading digital health company and provider of one of the only FDA-authorized at-home sample collection kits for COVID-19, today announced it has signed an agreement with leading life sciences company Ginkgo Bioworks to distribute Access Bio's FDA-authorized CareStart™ COVID-19 Antigen test to workplaces, clinics, schools, government offices, and health plans.
Everlywell's enterprise line of business has supplied COVID-19 testing to over 250 organizations, including some of the largest health plans in the nation.
The CareStart™ COVID-19 Antigen test from Access Bio is designed to be administered by healthcare professionals and includes a disposable rapid antigen testing lateral flow device to detect active COVID-19 infection in as little as 15 minutes. The agreement will enable Everlywell to distribute the rapid antigen test to organizations in need of diagnostic tests for COVID-19.
Following receipt of the first FDA emergency use authorization of its kind for its COVID-19 Test Home Collection Kit in May, Everlywell's enterprise line of business has supplied COVID-19 testing to over 250 organizations, including some of the largest health plans in the nation. As part of today's announcement, the company unveiled new digital tools to help organizations stay safe and compliant, along with new features for its reporting platform, Everlywell Lens, which debuted earlier in 2020 and has been used at universities, workplaces, and organizations across the country to support safer reopening or continued operations. The company now offers the following solutions for organizations in need of testing, reporting and compliance tools:
Enterprise Tools for Organizations
To learn more about Everlywell's full suite of testing and enterprise tools, please visit this site: everlywell.com/business/covid-19
Workplaces, clinics, schools, government offices, and health plans interested in learning more about rapid antigen testing can visit health.everlywell.com/carestart-rapid-antigen-test
Everlywell believes Americans deserve access to affordable lab tests and insightful, digitally-enabled results with actionable next steps. The company connects individuals to certified labs offering a suite of validated lab tests including Cholesterol, Heart Health, Fertility, STIs, Lyme Disease, Testosterone, Thyroid and more. Everlywell offers one of the only FDA-authorized at-home sample collection test kits for COVID-19, and was the first to provide access to at-home sample collection lab tests for fertility, high-risk HPV, and indoor & outdoor allergies. Prices are straightforward starting at $49 and tests are generally covered by Flexible Spending and Health Savings Accounts. Physician-reviewed, actionable test results from CLIA-certified labs are provided within days of sample receipt. The company also provides testing and engagement programs for health plans, healthcare organizations, and employers, including some of the largest health plans in the nation.
The Austin-based company was founded in 2015 and is advised by a Scientific Advisory Board that includes some of the nation's top scientists from Harvard, MIT, Google and NYU. Everlywell was selected as one of Fast Company's Most Innovative Companies in 2019. For more information please visit www.everlywell.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/everlywell-signs-agreement-to-distribute-fda-authorized-rapid-antigen-testing-for-organizations-and-public-health-agencies-301203414.html